US Trastuzumab Competition Heats Up
Mylan And Biocon’s Ogivri Biosimilar Leads New Wave Of Herceptin Rivals
Executive Summary
Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.
You may also be interested in...
Teva Sticks With 10% Discount For Trastuzumab
Teva and Celltrion have launched their Herzuma trastuzumab biosimilar in the US at a 10% discount to the Herceptin brand. The discount matches that offered for their Truxima rituximab biosimilar and compares to steeper discounts offered by competing biosimilars.
Mylan Reveals FDA Goal Date For Bevacizumab
Mylan and Biocon's global development alliance has so far led to two biosimilar launches in the US. A filing for a biosimilar of Genentech's Avastin (bevacizumab) submitted by Mylan may soon bring a third.
Mylan’s ‘Durable’ Model Has Helped Weather Storms
Mylan says its ‘durable’ business model has helped it to withstand pressures from adverse industry trends in 2019, boosted by $1bn in sales from newly-launched products. However, negative currency effects cut the firm’s sales growth from 3% at constant currencies to 1% as reported.